DBV Technologies (DBV) Q3 2024 earnings summary

Executive summary

• Focused on advancing Viaskin Peanut, a novel epicutaneous immunotherapy patch for peanut allergy in children, with parallel regulatory strategies in the US and EU for toddlers (1–3 years) and children (4–7 years).

• Ongoing pivotal Phase 3 VITESSE trial in 4–7-year-olds completed screening in Q3 2024; topline results expected Q4 2025.

• Regulatory progress includes FDA alignment on Accelerated Approval pathway for toddlers and EMA advice supporting a 1–7-year-old indication, pending new safety data.

• Cash and cash equivalents stood at $46.4 million as of September 30, 2024, with a cash runway into Q1 2025.

• Substantial doubt exists regarding the ability to continue as a going concern due to insufficient cash for the next 12 months.

Financial highlights

• Net loss for the nine months ended September 30, 2024, was $90.9M, compared to $61.5M in the prior year period.

• Operating income for the nine months was $3.6M, down from $6.9M year-over-year, due to the end of the NESTEC collaboration and lower research tax credits.

• Cash and cash equivalents were $46.4M as of September 30, 2024, down from $141.4M at year-end 2023.

• R&D expenses rose 48.5% year-over-year to $70.4M, driven by VITESSE trial enrollment and COMFORT study preparations.

• Operating expenses increased to $96.4M from $71.4M year-over-year, mainly driven by R&D for clinical trials.

Outlook and guidance

• Cash runway expected to fund operations into Q1 2025; substantial doubt exists regarding ability to continue as a going concern without additional financing.

• Plans to seek additional capital through equity, debt, or strategic partnerships to support product launch and ongoing R&D.

• If financing is unsuccessful, operations may be scaled back or rights to product candidates may be relinquished.

• BLA submission for Viaskin Peanut in toddlers anticipated after completion of COMFORT Toddlers safety study, with commercialization possible if approved.